[CAS NO. 1034688-30-6] GSK2018682
PRODUCTS SPECIFICATIONS [1034688-30-6]
DESCRIPTION [1034688-30-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 440.88 |
| Molecular Formula | C22H21ClN4O4 |
| SMILES | O=C(O)CCCN1C=CC2=C1C=CC=C2C3=NOC(C4=CC(Cl)=C(OC(C)C)N=C4)=N3 |
Summary
GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC 50 s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
IC50 & Target
pEC50: 7.7 (S1P1 receptor), 7.2 (S1P5 receptor) [1]
In Vitro
GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC 50 s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01431937 | GlaxoSmithKline |
Multiple Sclerosis, Relapsing-Remitting
|
October 10, 2010 | Phase 1 |
| NCT01387217 | GlaxoSmithKline |
Multiple Sclerosis
|
May 21, 2010 | Phase 1 |
| NCT01466322 | GlaxoSmithKline |
Multiple Sclerosis, Relapsing-Remitting
|
December 22, 2010 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 125 mg/mL ( 283.52 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2682 mL | 11.3410 mL | 22.6819 mL |
| 5 mM | 0.4536 mL | 2.2682 mL | 4.5364 mL |
| 10 mM | 0.2268 mL | 1.1341 mL | 2.2682 mL |